ClinicalTrials.gg
RecruitingNCT07229976Updated Oct 27, 2026

Clinical Efficacy of Thumbtack Needle for Chronic Insomnia in Perimenopausal and Menopausal Women

An interventional study of thumbtack needle and placebo thumbtack needle in Chronic Insomnia During Perimenopause and Menopause, sponsored by Huazhong University of Science and Technology. Recruiting at 8 sites in China. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 27, 2026Now RecruitingFirst site in China+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Planned enrollment
38th of 162
198 · median 88
Started
2026
with 27 others
No phase
123 of 198
56 open now
Primary completion
2029-12
later than 85 of 87 live
Registered
162nd of 198
by date

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 38th largest by planned enrollment of the 162 interventional ones that give a count, is one of 28 that started in 2026, is one of 123 with no phase, reaches primary completion later than 85 of the 87 other live ones, and was the 162nd registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

A multicenter, randomized, controlled, blinded clinical trial was conducted to evaluate the effects of thumbtack needle on sleep in patients with chronic insomnia during perimenopause and menopause. Randomly divided into a treatment group and a control group using the central area method, with 99 patients in each group. The treatment group received thumbtack needle treatment, while the control group received placebo thumbtack needle treatment. The treatment course for both groups was 4 weeks.

03

Conditions studied

  • Chronic Insomnia During Perimenopause and Menopause
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Diagnostic criteria for perimenopause and menopause:

  • Perimenopausal period: a period of time from one year before the last menstrual period to the first year after the last menstrual period. Having at least one menstrual period in the past 12 months, or being under 55 years old, undergoing hysterectomy or endometrial ablation, but not bilateral oophorectomy;
  • Menopause: No menstruation in the past 12 months, or bilateral oophorectomy, or age 55 years or older, who has undergone hysterectomy or endometrial ablation;

Diagnostic criteria for chronic insomnia:

●The diagnostic criteria for insomnia in the third edition of the International Classification of Sleep Disorders (ICSD-3) of the American Academy of Sleep Medicine (all criteria A to F must be met).

Inclusion criteria

Inclusion Criteria:

  • Women aged 40 to 65 who meet the diagnostic criteria for perimenopause and menopause mentioned above;
  • Evaluate ISI score ≥ 12 points through a scale;
  • Meets the diagnostic criteria for chronic insomnia mentioned above, i.e. ICSD-3 meets both criteria A to F;
  • Voluntarily participate in this study and sign an form.

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following conditions will not be included;

  • Use hormone replacement therapy, anti anxiety drugs, antidepressants, or medications to improve insomnia within one month;
  • Individuals with a history of diagnosed sleep disorders before menopause;
  • Combined with other sleep disorders such as obstructive sleep apnea, restless leg syndrome, etc;
  • Patients with malignant tumors, especially estrogen dependent tumors (such as breast cancer and endometrial cancer);
  • Recent (within 6 months) history of myocardial infarction, stroke, venous thrombosis, etc;
  • Patients with mental illnesses, such as severe depression and uncontrolled schizophrenia;
  • Serious disorder of endocrine system, such as uncontrolled hyperthyroidism, diabetes ketoacidosis, etc
  • Patients with coagulation disorders, such as hemophilia, long-term use of anticoagulants (warfarin, aspirin, etc.), etc;
  • Long term alcohol consumption history (more than 5 years, daily alcohol consumption exceeding 12 taels, not quitting drinking);
  • Engaged in night shift work (>3 times a week);
  • Individuals with infections, ulcers, burns, rashes, or scars at acupoints;
  • Previously received acupuncture treatment;
  • I do not agree to sign the form for this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
198 participants (estimated)

Study arms

  • Experimental
    thumbtack needle group

    The subject received thumbtack needle

    Other: thumbtack needle

  • Other
    Placebo thumbtack needle group

    The subject received placebo thumbtack needle

    Other: placebo thumbtack needle

Interventions

  • Otherthumbtack needle

    The treatment acupoints include bilateral Anmian Acupoint, bilateral Taichong acupoints, bilateral Neiguan acupoints, bilateral Sanyinjiao (SP6), and bilateral Zusanli (ST36) and Danzhong acupoints, a total of 11 acupoints. After 3 days of thumbtack needle retention, the patient went to the hospital where the doctor removed the thumbtack needle, disinfected the local skin, and received the next needle treatment. The patient received treatment twice a week (6 days) and rested for 1 day before continuing with the next treatment.

  • Otherplacebo thumbtack needle

    The placebo thumbtack needle group selected acupoints that were the same as the thumbtack needle group. Bilateral sleeping acupoints, bilateral Taichong acupoints, bilateral Neiguan acupoints, bilateral Sanyinjiao (SP6), bilateral Zusanli (ST36), and Danzhong acupoints are all treated with comforting acupressure.where the doctor removed the placebo thumbtack needle, disinfected the local skin, and received the next placebo thumbtack needle needle. The patient received treatment twice a week (6 days) and rested for 1 day before continuing with the next treatment.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index

    The Insomnia Severity Index (ISI) is a self-assessment tool used to evaluate the severity of insomnia. The ISI scale consists of 7 items, each rated on a scale of 0-4, with a total score range of 0-28 points. Evaluate the difference in scores between the Insomnia Severity Index (ISI) scale at the end of week 4 and baseline ISI scores.

    Time frame: 4 weeks

Secondary outcomes

  1. Pittsburgh sleep quality index

    The Pittsburgh Sleep Quality Index (PSQI) is a widely used sleep quality assessment tool internationally. Evaluate the difference between the PSQI score at the end of week 4 and the baseline PSQI score.

    Time frame: 4 weeks

  2. Epworth Sleepiness Scale

    The Epworth Sleepiness Scale (ESS) is a self-assessment tool used to evaluate an individual's level of daytime sleepiness. Evaluate the difference between the ESS score at the end of week 4 and the baseline ESS score.

    Time frame: 4 weeks

  3. Fatigue Severity Scale

    The Fatigue Severity Scale (FSS) is currently one of the most commonly used scales for assessing fatigue symptoms in clinical practice. Assess the difference between FSS score at the end of week 4 and baseline FSS score .

    Time frame: 4 weeks

  4. Zung Self Rating Anxiety Scale

    The Zung Self Rating Anxiety Scale (SAS) is used to assess the severity of an individual's anxiety symptoms over the past week. Evaluate the difference between the SAS score at the end of week 4 and the baseline SAS score.

    Time frame: 4 weeks

  5. Zung Self Rating Depression Scale

    The Zung Self Rating Depression Scale (SDS) is currently one of the most widely used self-assessment scales for depression. Evaluate the difference between SDS score at the end of week 4 and baseline SDS score.

    Time frame: 4 weeks

  6. Sleep efficiency

    Sleep efficiency refers to the ratio of actual sleep time to bed rest time. Evaluate the difference between sleep efficiency at the end of week 2 and week 4 and baseline sleep efficiency.

    Time frame: 2 weeks,4 weeks

  7. wake-up time after sleep onset

    Assess the difference between the wake-up time after sleep onset at the end of week 2 and week 4, and the wake-up time after baseline sleep onset.

    Time frame: 2 weeks, 4 weeks

  8. the number of awakenings per night

    Evaluate the difference between the number of awakenings per night at the end of week 2 and week 4 compared to the baseline number of awakenings per night.

    Time frame: 2 weeks, 4 weeks

  9. The latent period of sleep onset

    The latent period of sleep onset refers to the time it takes from getting ready to sleep to actually entering a state of sleep. Evaluate the difference between the sleep onset latency at the end of week 2 and week 4 and the baseline sleep onset latency.

    Time frame: 2 weeks, 4 weeks

  10. Total sleep time

    Total sleep time refers to the total duration of continuous or intermittent sleep that an individual experiences within a certain period of time (usually 24 hours). Evaluate the difference between the total sleep time at the end of week 2 and week 4 and the baseline total sleep time.

    Time frame: 2 weeks, 4 weeks

  11. the average wake-up time

    Evaluate the difference between the average wake-up time at the end of week 2 and week 4 and the baseline average wake-up time.

    Time frame: 2 weeks, 4weeks

  12. Corticotropin-Releasing Hormone

    Corticotropin Releasing Hormone (CRH) is a peptide hormone secreted by the hypothalamus. Evaluate the difference in serum CRH concentration between the thumbtack needle group and the placebo thumbtack needle group at the end of week 4.

    Time frame: 4 weeks

  13. Norepinephrine

    Norepinephrine is both a neurotransmitter and a hormone. Evaluate the difference in serum Norepinephrine concentration between the thumbtack needle group and the placebo thumbtack needle group at the end of week 4.

    Time frame: 4 weeks

  14. Adrenaline

    Adrenaline is a hormone and neurotransmitter secreted by the adrenal medulla. Evaluate the difference in serum Adrenaline concentration between the thumbtack needle group and the placebo thumbtack needle group at the end of week 4.

    Time frame: 4 weeks

  15. 5-hydroxytryptamine

    5-hydroxytryptamine (5-HT), also known as serotonin, is an important monoamine neurotransmitter that plays a crucial role in the physiological and psychological functions of the human body. Evaluate the difference in serum 5-HT concentration between the thumbtack needle group and the placebo thumbtack needle group at the end of week 4.

    Time frame: 4 weeks

  16. Gamma aminobutyric acid

    Gamma aminobutyric acid (GABA) is a non protein amino acid widely present in the human body, animals, and plants, and is also an important inhibitory neurotransmitter in the central nervous system. Evaluate the difference in serum GABA concentration between the thumbtack needle group and the placebo thumbtack needle group at the end of week 4.

    Time frame: 4 weeks

  17. Dopamine

    Dopamine is an important neurotransmitter that has a wide range of effects on human physiological and psychological functions. Evaluate the difference in serum Dopamine concentration between the thumbtack needle group and the placebo thumbtack needle group at the end of week 4.

    Time frame: 4 weeks

  18. Melatonin

    Melatonin is an endogenous hormone secreted by the pineal gland of the human brain. Evaluate the difference in serum melatonin concentration between the thumbtack needle group and the placebo thumbtack needle group at the end of week 4.

    Time frame: 4 weeks

  19. β - endorphin

    Evaluate the difference in serum β - endorphin concentration between the placebo group and the placebo group at the end of week 4.

    Time frame: 4 weeks

  20. insomnia remission rate

    The proportion of patients who no longer meet the diagnosis of insomnia after treatment among those receiving insomnia treatment. The diagnosis of insomnia refers to the International Classification of Sleep Disorders, ICSD-3

    Time frame: 4 weeks

  21. Insomnia Treatment Response Rate

    The proportion of patients receiving insomnia treatment whose Insomnia Severity Index score decreased by 8 or more points after treatment

    Time frame: 4 weeks

  22. Insomnia Severity Index

    The Insomnia Severity Index (ISI) is a self-assessment tool used to evaluate the severity of insomnia. The ISI scale consists of 7 items, each rated on a scale of 0-4, with a total score range of 0-28 points. Evaluate the difference in scores between the Insomnia Severity Index (ISI) scale at the end of week 2 and baseline ISI scores.

    Time frame: 2 weeks

  23. Menopause Rating Scale

    Menopause Rating Scale(MRS) is a widely used tool in clinical practice and research to assess the type and severity of menopause-related symptoms, particularly the subjective experience over the past 4 weeks.

    Time frame: 4 weeks

07

Study locations

8 of 8 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2029, 45 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 45 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Mar 20, 2026
Primary completionEst.
Dec 30, 2029
CompletionEst.
Dec 30, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
8 sites added — first site in China
Show 8 added (8 China)
  • Chibi Maternal and Child Health Hospital · Chibi, China
  • Jingzhou Hospital of Traditional Chinese Medicine · Jingzhou, China
  • Qianjiang Central Hospital · Qianjiang, China
  • Wuhan Children's Hospital · Wuhan, China
  • Renmin Hospital of Wuhan University · Wuhan, China
  • Rehabilitation Center, Wuhan Puren Hospital · Wuhan, China
  • Xiaogan Maternal and Child Health Care Hospital · Wuhan, China
  • Aksu Prefecture Maternal and Child Health Hospital · Aksu, China
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    8 sites added — first site in China
    Show 8 added (8 China)
    • Chibi Maternal and Child Health Hospital · Chibi, China
    • Jingzhou Hospital of Traditional Chinese Medicine · Jingzhou, China
    • Qianjiang Central Hospital · Qianjiang, China
    • Wuhan Children's Hospital · Wuhan, China
    • Renmin Hospital of Wuhan University · Wuhan, China
    • Rehabilitation Center, Wuhan Puren Hospital · Wuhan, China
    • Xiaogan Maternal and Child Health Care Hospital · Wuhan, China
    • Aksu Prefecture Maternal and Child Health Hospital · Aksu, China
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07229976
Responsible party
Dongmei Huang (Dr, Huazhong University of Science and Technology) — Principal investigator
First posted
Nov 17, 2025
Start date
Mar 20, 2026
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Oct 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion